Cantargia Logo

Cantargia

Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.

CANTA | ST

Overview

Corporate Details

ISIN(s):
SE0006371126 (+3 more)
LEI:
549300GKWRT7RXI4VS85
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Cantargia is a biotechnology company developing antibody-based treatments for life-threatening diseases, focusing on cancer and autoimmune/inflammatory conditions. The company's core technology targets the interleukin-1 receptor accessory protein (IL1RAP). Its lead clinical candidate, nadunolimab (CAN04), is an antibody in Phase II development for cancer therapy. Its second program, CAN10, an antibody for autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical, validating the potential of Cantargia's proprietary IL1RAP-targeting platform.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 07:30
Board/Management Information
Cantargia utser Dr Wolfram Dempke till Chief Medical Officer
Swedish 102.8 KB
2025-10-02 07:30
Board/Management Information
Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer
English 103.2 KB
2025-09-11 07:30
M&A Activity
Cantargia closes the acquisition of CAN10 by Otsuka
English 104.2 KB
2025-09-11 07:30
M&A Activity
Cantargia slutför Otsukas förvärv av CAN10
Swedish 103.9 KB
2025-08-21 07:00
Interim Report
Swedish 3.5 MB
2025-08-21 07:00
Interim Report
English 3.5 MB
2025-08-18 18:25
Board/Management Information
Cantargia utnämner Dr Hilde Steineger till verkställande direktör
Swedish 107.1 KB
2025-08-18 18:25
Board/Management Information
Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
English 107.8 KB
2025-07-17 21:30
Regulatory News Service
Cantargia announces preliminary topline efficacy results from the phase 2 TRIFO…
English 117.3 KB
2025-07-17 21:30
Earnings Release
Cantargia meddelar preliminära topline-effektresultat från fas 2-studien TRIFOU…
Swedish 118.2 KB
2025-07-15 08:45
M&A Activity
Cantargia tillkännager försäljningen av IL1RAP immunologiprogrammet CAN10 till …
Swedish 111.6 KB
2025-07-15 08:45
M&A Activity
Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by O…
English 111.5 KB
2025-07-08 10:17
Major Shareholding Notification
Swedish 9.5 KB
2025-06-17 19:45
Capital/Financing Update
Cantargia tecknar avtal om lånefacilitet om 50 miljoner kronor, som förlänger b…
Swedish 107.1 KB
2025-06-17 19:45
Capital/Financing Update
Cantargia signs SEK 50 million financing facility agreement, extending cash run…
English 107.4 KB

Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cantargia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-19 Nedjad Losic Other Buy 21,375 33,131.25 SEK
2025-01-02 Antonius Franciscus Berkien Other Other 21,621 39,998.85 SEK
2024-12-20 Göran Forsberg Other Other 152,206 281,581.10 SEK
2024-12-20 Nedjad Losic Other Other 12,875 23,818.75 SEK
2024-12-09 Antonius Franciscus Berkien Other Buy 3,741 6,733.80 SEK
2023-01-19 Nedjad Losic Other Buy 3,918 29,110.74 SEK
2023-01-17 Göran Forsberg Other Buy 17,000 140,250.00 SEK
2023-01-17 Bengt Jöndell Other Buy 6,500 54,665.00 SEK
2022-07-28 Göran Forsberg Other Other 91,765 344,118.75 SEK
2022-07-28 Thoas Fioretos Other Other 78,400 294,000.00 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.